Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017, University of York
Bone marrow protein a ‘magnet’ for passing prostate cancer cells
The team blocked a signal in the cancer cell with a non-toxic drug. Credit: University of York

Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Now that this mechanism has been identified, however, scientists at York have found a way to block the signal in the cells, disabling the cell and preventing it from multiplying at a new site in the body.

Their research showed that the , which normally functions to reduce inflammation after infections, has a key-like structure that locks on to opposite receptors on the stem cells of . This allows cancer cells that have spread from the prostate to 'dock' with the protein in the bones and multiply to form a new tumour.

Once the prostate cancer has attached to the protein, a signal is sent from the surface of the cancer to the nucleus of the cell, telling it that it can start to grow.

Like a 'space rocket'

Professor Norman Maitland, from the University's Department of Biology, said: "We have always known that the two places where prostate cancer spreads are the bones and lymph nodes, but we have not fully understood why these two locations are preferred.

"If we imagine the prostate cancer cell as a floating 'space rocket' and the only way for it to perform its mission is to 'dock' with another 'space vehicle', we start to get a picture of what happens when a cancer cell moves around the body in search of a new home.

"Without this docking station, the 'ship', or cell, will just float around, not causing any further harm. The receptors on the '', or the protein in bone, act like a magnet for the receptors on the of the cancer and once it is 'docked', getting rid of the cancer becomes much harder."

Blocking the signal

Replicating this 'docking process' in human , the team were able to identify the signal going into the nucleus of the cancer cell and blocked it with a non-toxic drug that has previously been tested for treatment of Allergic Asthma.

They found that the drug inhibits the signal, allowing the cancer cell to survive, but ultimately disabling its ability to spread. This could mean that cancer spread can be slowed down or be made more receptive to cell death following traditional treatments such as chemotherapy.

Drug discovery

Professor Maitland said: "We know that this works in human , but what we now need to find is the correct dosage of the drug in patients, and whether it will buy a man more time to fight his cancer or even stop the spread of cancer altogether".

"Clinical trials are some way off, but this is a positive and exciting step forward in tackling this disease and reducing the number of deaths."

The research is published in the journal Oncogenesis

Explore further: ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

More information: G Nappo et al. The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling, Oncogenesis (2017). DOI: 10.1038/oncsis.2017.23

Related Stories

ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

August 2, 2017
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics, Inc., USA and ...

Body size and prostate cancer risk

July 14, 2017
Prostate cancer is the most common cancer in men in Europe and the second most frequently diagnosed cancer in men worldwide.

Disrupting prostate cancer 'homing signal' could hold promise for new treatments

March 20, 2017
New King's College London research sheds light on the cellular mechanisms which enable cancer cells to escape the prostate and spread to other parts of the body.

Vitamin A could prevent the spread of prostate cancer

April 16, 2013
(Medical Xpress)—Vitamin A could help treat and prevent the spread of prostate cancer, according to research published today (Monday, April 15th) in Oncogenesis.

Potential cholesterol-lowering drug molecule has prostate cancer fighting capabilities

April 14, 2016
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting ...

Tumor cells in blood samples could predict prostate cancer spread

November 3, 2016
Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute ...

Recommended for you

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.